Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Expert review of pharmacoeconomics & outcomes research - 10(2010), 2 vom: Apr., Seite 103-115 |
| Beteiligte Personen: |
Best, Jennie H [VerfasserIn] |
|---|
| Umfang: |
12 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1839347821 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC1839347821 | ||
| 003 | DE-627 | ||
| 005 | 20230508131051.0 | ||
| 007 | tu | ||
| 008 | 100414s2010 xx ||||| 00| ||und c | ||
| 028 | 5 | 2 | |a sw100413_1 |
| 035 | |a (DE-627)OLC1839347821 | ||
| 035 | |a (DE-599)GBVOLC1839347821 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 082 | 0 | 4 | |a 610 |
| 100 | 1 | |a Best, Jennie H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer |
| 264 | 1 | |c 2010 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 700 | 1 | |a Garrison, Louis P |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of pharmacoeconomics & outcomes research |d London : Taylor & Francis, Taylor und Francis Group, 2001 |g 10(2010), 2 vom: Apr., Seite 103-115 |w (DE-627)502545127 |w (DE-600)2208481-2 |w (DE-576)473534010 |x 1473-7167 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2010 |g number:2 |g month:04 |g pages:103-115 |g extent:12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-WIW | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2010 |e 2 |c 4 |h 103-115 |g 12 | ||